The most recent and prominent United States (US) attempt to limit cooperation with Chinese life science businesses has stalled, but is hardly dead. Current Speaker of the House Mike Johnson said he intends to have the BIOSECURE Act signed into law before the end of 2024.[1] Irrespective of the impasse,...
Tag: protectionism
March 25, 2024
In January 2024, Congressman Mike Gallagher, the Chair of the United States (US) House Committee on the Chinese Communist Party, introduced the “Biosecure Act,” which prohibits the US government (USG) from “procuring or obtaining biotechnology equipment or services produced or provided by a biotechnology company of concern,” participating in a...
September 21, 2022
In my last blog, I detailed China’s continuing shortcomings with protecting intellectual property (IP) rights (IPR) and the emergence of new challenges. The question arises as to why these problems persist even though it has been more than 20 years since China joined the World Trade Organization (WTO), is...
December 13, 2020
In May 2020, China’s two-track “dual circulation” strategy (DSC) came to light. An internal circulation track—the “mainstay”—encompasses domestic consumption and production. An external circulation track entails more opportunities for foreign direct investment (FDI) and efforts to expand China’s external connections. China will use the former to support growth and its...
October 29, 2018
In late October, the one-and-a-half-day Global Backlash conference, hosted by UC Berkeley and co-organized by the Mr. & Mrs. S.H. Wong Center for the Study of Multinational Corporations (Wong MNC Center), Berkeley APEC Studies Center (BASC), and Center for Long-Term Cybersecurity (CLTC), took place at the University of California, Berkeley...
